^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TTN mutation

i
Other names: TTN, Titin, Rhabdomyosarcoma Antigen MU-RMS-40.14, Connectin, Cardiomyopathy Dilated 1G (Autosomal Dominant), LGMDR10, LGMD2J, CMPD4, EOMFC, HMERF, MYLK5, SALMY, CMD1G, CMH9, TMD
Entrez ID:
Related biomarkers:
Twitter
Trials
5d
Identification and validation of a TTN-associated immune prognostic model for skin cutaneous melanoma. (PubMed, Front Genet)
Additionally, the response to chemotherapeutic agents was higher in the low-risk group than in the high-risk group, which may be related to the long survival in the low-risk group. Collectively, we constructed and validated a TM-IPM using four immune-related genes and analyzed the potential mechanisms of TM-IPM to predict patient prognosis and response to immunotherapy from an immunological perspective.
Journal • Tumor mutational burden • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • TTN (Titin) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FCGR2A (Fc fragment of IgG receptor IIa)
|
TMB-H • TTN mutation
1m
Analyzing TCGA Data to Identify Gene Mutations Linked to Hepatocellular Carcinoma in Asians. (PubMed, Gastrointest Tumors)
We also found that the TP53 mutation predicts worse outcomes within the non-Asian cohort but not within the Asian cohort. Our findings can improve cancer care in the Asian population through better disease prognostication, evaluations for potential targeted therapy, and a deeper understanding of liver cancer pathogenesis.
Journal
|
TP53 (Tumor protein P53) • TTN (Titin) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • CSMD1 (CUB And Sushi Multiple Domains 1)
|
TP53 mutation • TTN mutation
2ms
A pyroptosis expression pattern score predicts prognosis and immune microenvironment of lung squamous cell carcinoma. (PubMed, Front Genet)
Compared with the high-PEPScore subgroup, the low-PEPScore subgroup had significantly better OS, higher TP53 and TTN mutation rate, higher infiltration of T follicular helper cells and CD8 T cells, and may benefit more from chemotherapeutic drugs, immunotherapy and radiotherapy. PEPScore is a prospective prognostic model to differentiate prognosis, molecular and immune microenvironmental features, as well as provide significant guidance for selecting clinical therapies.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • TTN (Titin) • CSF2 (Colony stimulating factor 2) • TSLP (Thymic Stromal Lymphopoietin) • AKAP12 (A-Kinase Anchoring Protein 12)
|
TP53 mutation • TTN mutation
6ms
Driver Gene Alterations in Malignant Progression of Gastric Cancer. (PubMed, Front Oncol)
Further research identified six GC-related driver genes associated with the levels of immune infiltration of different immune cells and the majority of immune markers. Our mutation-based study of driver oncogenes identified potential drug targets in GC.
Journal
|
TP53 (Tumor protein P53) • LRP1B (LDL Receptor Related Protein 1B) • MUC16 (Mucin 16, Cell Surface Associated)
|
TP53 mutation • LRP1B mutation • TTN mutation
6ms
TTN Mutations Predict a Poor Prognosis in Patients with Thyroid Cancer. (PubMed, Biosci Rep)
Nomograms also confirmed the prognostic values of the TTN gene in THCA.Conclusions In summary, our results demonstrated that TTN gene mutations predict poor prognosis in patients with THCA. This is the first study to research TTN gene mutations in THCA and to investigate their prognostic value in THCA.
Journal
|
TTN (Titin)
|
TTN mutation
7ms
Gene Mutations Related to Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Front Pediatr)
Upon statistical analysis, TTN and NOTCH1 mutations were found to be associated with prednisone resistance...Our study is the first to demonstrate the association between TTN mutation and glucocorticoid resistance in ALL. Our findings could guide strategies for overcoming drug resistance and aid in the development of drug targets.
Journal
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NOTCH1 (Notch 1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MUC16 (Mucin 16, Cell Surface Associated) • PHF6 (PHD Finger Protein 6)
|
TP53 mutation • NOTCH1 mutation • MUC16 mutation • PHF6 mutation • TTN mutation
|
prednisone
8ms
A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. (PubMed, Front Pharmacol)
In contrast, patients in the IPI-low subgroup were exhibited characters as p53 signaling pathways activation, higher TP53 and TTN mutation rate, more infiltrations of resting memory CD4 T cells, macrophages M2, immune-suppressive response and less benefit from ICB treatment. IPI is a potentially valuable prognostic evaluation method for LUAD, which works well in the benefit predicting of LUAD patients within ICB treatment.
Journal
|
CD8 (cluster of differentiation 8) • TTN (Titin) • CD4 (CD4 Molecule) • ADRB2 (Adrenoceptor Beta 2)
|
TP53 mutation • TTN mutation
9ms
Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer. (PubMed, Front Mol Biosci)
Finally, four drugs (panobinostat, lenvatinib, everolimus, and temsirolimus) were found to have potential therapeutic implications for patients with a high-risk score. Our findings highlight that the TME and DNA methylation-related prognostic signature can accurately predict the prognosis of CC and may be important for stratified management of patients and precision targeted therapy.
Clinical data • Journal • Tumor Mutational Burden • IO biomarker • Epigenetic controller
|
TMB (Tumor Mutational Burden)
|
TTN mutation
|
everolimus • Lenvima (lenvatinib) • Torisel (temsirolimus) • Farydak (panobinostat)
12ms
Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic. (PubMed, J Leukoc Biol)
The overall survival and relapse-free survival of adult patients with ALL were poorer than those of pediatric patients with ALL (p = 0.002 and p < 0.001, respectively). This genomic landscape enhances the understanding of the biologic differences in ALL between the 2 populations and provides insight for developing therapeutic approaches.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ARID1A (AT-rich interaction domain 1A) • IKZF1 (IKAROS Family Zinc Finger 1) • CREBBP (CREB binding protein)
|
KRAS mutation • ARID1A mutation • CREBBP mutation • TTN mutation
12ms
TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients. (PubMed, Transl Cancer Res)
Additionally, TTN/TP53 double mutation-initiated high rate of chemotherapy response were largely concentrated within LUAD and LUSC patients whose anatomic neoplasm subdivision were located in the upper lung. Collectively, TTN/TP53 co-mutation is possibly served as an effective predictor for OS and chemotherapy response in lung cancer.
Journal
|
TP53 (Tumor protein P53) • TTN (Titin)
|
TP53 mutation • TTN mutation
1year
Mutations in the TTN Gene are a Prognostic Factor for Patients with Lung Squamous Cell Carcinomas. (PubMed, Int J Gen Med)
TTN mutation is associated with TMB, and is positively correlated with prognosis of LUSC. Therefore, this mutation may serve as a potential prognostic indicator of LUSC.
Clinical • Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • TTN (Titin)
|
TMB-H • TTN mutation
1year
Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation. (PubMed, BMC Pulm Med)
Taking the mutant group as a reference, LUAD patients in the mutant group had significant differences in somatic mutations, mRNA-seq, miRNA-seq, immune infiltration, and immunomodulators, indicating that TP53 mutation plays a crucial role in the occurrence and development of LUAD.
Clinical • Journal
|
TP53 (Tumor protein P53) • AFP (Alpha-fetoprotein) • TTN (Titin) • CD4 (CD4 Molecule) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CSMD3 (CUB And Sushi Multiple Domains 3)
|
TP53 mutation • TTN mutation
1year
Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer. (PubMed, J Immunol Res)
In summary, we constructed a novel GIMiSig that could stratify GC patients into distinct risk groups that have different survival outcomes and immunotherapy efficacy. The results may provide new clues for improving GC outcomes.
Journal • IO biomarker
|
TTN (Titin) • UBQLN4 (Ubiquilin 4)
|
TTN mutation • UBQLN4 overexpression
1year
Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma. (PubMed, Front Cell Dev Biol)
Moreover, according to the CIBERSORT algorithm, we revealed that TTN mutation enhanced the antitumor immune response. In conclusion, TTN may have important clinical implications for relevant immune therapy of lung squamous carcinoma.
Journal • Tumor Mutational Burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • LRP1B (LDL Receptor Related Protein 1B) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • COL1A1 (Collagen Type I Alpha 1 Chain) • CSMD3 (CUB And Sushi Multiple Domains 3) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • USH2A (Usherin) • RYR3 (Ryanodine Receptor 3)
|
TP53 mutation • TMB-H • TTN mutation
over1year
Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering. (PubMed, Biomed Pharmacother)
The findings provided novel insights into the GC subtypes through integrative analysis of five -omics data by ten clustering algorithms. These could provide potential clinical therapeutic targets based on the specific molecular features.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • MUC16 (Mucin 16, Cell Surface Associated)
|
ARID1A mutation • MUC16 mutation • TTN mutation
|
cisplatin • paclitaxel • 5-fluorouracil
over1year
Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients. (PubMed, Front Oncol)
TTN-MT is associated with significantly prolonged OS in LUAD patients. Additionally, TTN-MT is related to high immunogenicity and inflammatory TIME, suggesting that TTN-MT may be a potential predictive marker for patients with LUAD to accept ICIs.
Clinical • Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • TTN (Titin)
|
TTN mutation
over1year
Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. (PubMed, Genes (Basel))
Expression of selected KLK6-associated genes was validated in a subset of paired normal and tumor CRC patient-derived organoid cultures. The performed analyses identified KLK6 itself and a set of genes, which are co-expressed with KLK6, as potential clinical biomarkers for the management of the CRC disease.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • TGFB1 (Transforming Growth Factor Beta 1)
|
KRAS mutation • TTN mutation
over1year
Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand. (PubMed, Cancers (Basel))
These findings indicate that the mutational profile of cfDNA accurately reflected that of HCC tissue and suggest that cfDNA could serve as a useful biomarker for diagnosis and prognosis in Thai HCC patients. In addition, we demonstrated the use of the pocket-sized sequencer of Oxford Nanopore Technology to detect copy-number variants in HCC tissues that could be applied for onsite clinical detection/monitoring of HCC.
Clinical • Journal
|
TP53 (Tumor protein P53)
|
TTN mutation
over1year
[VIRTUAL] GENOMIC HETEROGENEITY CONTRIBUTED TO THE DIFFERENT PROGNOSIS OF ADULT AND PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2021)
The overall survival(OS) and relapse free survival (RFS) of adult ALL were poorer than pediatric ALL(P=0.003, P<0.001, respectively). Conclusion This genomic landscape enhanced the understanding of the biological differences of ALL between the two populations and provided a clue for novel therapeutic approaches.
Clinical • BRCA Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • DNMT3A (DNA methyltransferase 1) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • NOTCH1 (Notch 1) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • ATRX (ATRX Chromatin Remodeler) • CREBBP (CREB binding protein) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • EP300 (E1A binding protein p300)
|
KRAS mutation • ARID1A mutation • CREBBP mutation • TTN mutation • SETD2 mutation
almost2years
Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. (PubMed, Transl Lung Cancer Res)
The presence of mutated TTN in pre-treatment peripheral blood was associated with favorable objective response and survival with ICB administration. Therefore, circulatory TTN mutation may be applicable for guiding ICB immunotherapy in patients with NSCLC.
Clinical • Journal • Checkpoint inhibition • IO biomarker
|
TTN (Titin)
|
TTN mutation
almost2years
TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer. (PubMed, J Cell Mol Med)
Bioinformatic algorithm assessment of immunotherapy responses also confirmed this conclusion, and the 'Double-Hit' phenotype was found to be a better predictor of immunotherapy than PD-L1, PD-1, CTLA-4, TMB and microsatellite status. This study revealed CRC patients with TTN/OBSCN 'Double-Hit' was significantly associated favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy.
Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
|
POLE mutation • TTN mutation
almost2years
Clinical • Journal
|
TP53 (Tumor protein P53) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
|
TP53 mutation • TTN mutation
2years
Spontaneous mutations in the single TTN gene represent high tumor mutation burden. (PubMed, NPJ Genom Med)
TTN mutation was enriched in samples possessing high immunostimulatory signatures. We suggest that the mutation load within TTN represents high TMB status.
Journal • Tumor Mutational Burden • MSi-H Biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • TTN (Titin)
|
TMB-H • MSI-H/dMMR • TTN mutation